Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors - Wikidata - wikimedia - TriplyDB

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

http://www.wikidata.org/entity/Q35842206

about

FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives Normal and neoplastic urothelial stem cells: getting to the root of the problem Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Emerging critical role of molecular testing in diagnostic genitourinary pathology Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Role of angiogenesis in urothelial bladder carcinoma MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31 Integrative modelling of the influence of MAPK network on cancer cell fate decision A place for precision medicine in bladder cancer: targeting the FGFRs.Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Spatial normalization of array-CGH data.CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer Recurrent and multiple bladder tumors show conserved expression profiles Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer Potential new urinary markers in the early detection of bladder cancer.Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.Urothelial carcinoma: stem cells on the edge.Chromosomal imbalances in human bladder urothelial carcinoma: similarities and differences between biopsy samples and cancer stem-like cells Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.Deregulation of Rab and Rab effector genes in bladder cancer.Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder.Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report.Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.

P2860

Q24804513-8039C7A6-8D56-464A-932B-CAEA8177D415 Q24805521-EC775837-F620-4CE9-85FA-9B49180834E3 Q26765922-C6829424-C561-4B3F-8961-23CCD562DEB6 Q26771263-7C3A89D0-7296-41DD-B8A5-3C1FDA59BF78 Q26825948-F6AC3765-785E-47C7-9E05-D5F867EDC03A Q26998790-7BBAB993-BFB1-4E69-96E0-A755C7AA3FFF Q27021371-B3DABAC7-AFD0-4F4B-BA24-D6FEA7FDA1DA Q27851612-8CA24C52-3C36-41AC-ADF2-136CCB476295 Q28080330-FB840E41-52FC-4F3F-9B56-D4A098CB794F Q28305980-E7C2C644-5EA7-4199-9608-696B5C8B9E5A Q28534949-07E954D6-D458-4453-8624-905F79336ABD Q30249143-85AF0CEF-92C0-4994-A37A-505BF03B7A44 Q30433431-FFA67BB8-B029-4260-A766-4CC7F09B0EA3 Q30439612-8E9D0693-E36E-4642-A8D7-C39930A6BC24 Q30446429-9BD1E3ED-CCAA-4488-8FFF-FBBAC3DFA8E7 Q30857433-7D4814C7-48A7-4ADB-96F3-419CB2398FE5 Q31041638-2FEE3963-23E5-4055-90C1-1781A841D012 Q31120339-080412CE-F029-4BB8-80FC-600202C32830 Q31148688-391A59BE-0623-44F3-835C-EF8371E18804 Q33292711-44774967-FF9A-43B7-8D35-056032AE38B7 Q33347849-CD95F32F-4124-4C89-A457-DE5D270D9E7A Q33487902-940ABCB9-F1B1-47B3-A8D9-F8F0C3A6D2A7 Q33554443-BA0F0DF1-DE3F-4CB3-A9BF-FB40B40420A8 Q33657098-29C16369-A0B5-4FB5-A674-455F11A130B2 Q33697172-34206A93-61B6-41B6-9919-8CE07975E94F Q33703786-BF7FBC08-7100-4A2E-9CA3-4D1EC82CF521 Q33745140-31151A24-130E-4BC3-90A3-119D4CE6ADE0 Q33891125-ABED4633-069D-4147-AB5E-C27D8F43621D Q34071175-96282B2E-B750-4C86-937D-09FC1A5ECA00 Q34092411-4B4E0F1B-D73C-4A76-87FB-926DEA1B6A77 Q34174124-66A92BA5-8D6B-49EE-9FB1-57F54C70C150 Q34203924-7BB1817E-7422-4060-9A83-11DFAA3F69F3 Q34299788-A159C265-BA10-440A-ADDB-78E710202DAD Q34314461-F0960046-3051-4E25-ABBE-E212F49EEAE2 Q34314756-AAE5F542-869E-45AA-AFCD-3CF1534645BD Q34370868-5B179E10-F6D0-4ED7-8C59-B59C6578D433 Q34395643-4927FE01-231F-4D03-B8B2-BBF41BBED6E2 Q34462001-0A7C5D80-4EBB-4CBA-BE02-19AC4D906D2B Q34524813-08C082DD-C3DD-4738-A493-1ED205461343 Q34611953-4932B8F2-9EAE-4441-8AE3-7DB6ABD60AAE

P2860

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

http://www.wikidata.org/entity/Q35842206

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@ast

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@en

type

label

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@ast

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@en

prefLabel

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@ast

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@en

P1433

Q35842206-5AA6956F-D8DF-47FA-96A5-E71D64C5A73D

P1476

Q35842206-2903EEC6-CAFE-49CD-B745-2E2D42B65673

P2093

Q35842206-0FEC5B38-3786-4678-94C6-EFE8CBC184FD

Q35842206-128A4A12-DAFA-4DE0-BFAD-7C61BE84BD3A

Q35842206-365519AA-D2E0-46A3-BCB9-C8586A32C8E9

Q35842206-45024085-D829-4299-8A86-3BD90D279C3F

Q35842206-4D564443-641E-4A90-8F83-98536DF9532E

Q35842206-5EED81F9-A180-4365-B159-EDC9A9C4522A

Q35842206-646DB97B-4FC6-49A4-BBAB-02CEAF6E29AE

Q35842206-65569452-41A1-4CD3-90CE-71232B5457D0

Q35842206-7E2D0644-9F62-472B-8918-E62F8836B5FA

Q35842206-9833E539-F37D-4654-9A71-047961CCF9FA

P2860

Q35842206-16CBE41A-C906-4C6D-A276-60B5D8FF06A7

Q35842206-22872CB6-29A6-42D6-8554-ED2253494D9B

Q35842206-27018EDD-F2A7-493A-BCA0-BF6F230685A5

Q35842206-2A63E24E-80EC-47F5-920D-B4FF637CDF57

Q35842206-2D6BE841-41CE-40FB-AC21-0367E43EA424

Q35842206-36663C17-CF78-4FD1-A474-DD89F2B4053F

Q35842206-4ABAD167-CCAC-49BA-839D-0DE0FB295CE7

Q35842206-56D682C2-F449-4ABC-80D1-574523A99432

Q35842206-6D71AC69-C99E-4277-BB49-08A260EE5BBC

Q35842206-6EB5C21B-6F09-4B21-B641-E28AD104E997

P304

Q35842206-13E5ACD3-4E21-48D4-A6AA-BECE93C94DD3

P31

Q35842206-CF6E8BF5-470E-40CA-A058-36C330A86F91

P356

Q35842206-B388269F-949B-49C7-BD91-72A73794982F

P407

Q35842206-164FDA6A-602B-4DF6-8D2E-9049B4279AF4

P433

Q35842206-9A81BE85-640B-4205-BB56-FCA967252CB3

P478

Q35842206-BF8BF042-0ED7-4817-BE53-4335357EC28B

P577

Q35842206-01B3F04F-302B-4F92-BE1A-83C05F8BB67A

P698

Q35842206-14F49BE9-047D-41F4-A0DF-F7D0F5300E42

P932

Q35842206-38F8E878-61E5-4717-AC74-4D98C190F7AF

P356

S0002-9440(10)64665-2

P1433

The American Journal of Pathology

P1476

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

@en

P2093

B Van Rhijn

http://www.w3.org/2001/XMLSchema#string

C Billerey

http://www.w3.org/2001/XMLSchema#string

C C Abbou

http://www.w3.org/2001/XMLSchema#string

D Chopin

http://www.w3.org/2001/XMLSchema#string

D Ricol

http://www.w3.org/2001/XMLSchema#string

E S Zafrani

http://www.w3.org/2001/XMLSchema#string

F Radvanyi

http://www.w3.org/2001/XMLSchema#string

J B Lahaye

http://www.w3.org/2001/XMLSchema#string

J Bonaventure

http://www.w3.org/2001/XMLSchema#string

J P Thiery

http://www.w3.org/2001/XMLSchema#string

P2860

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene

Structural and functional diversity in the FGF receptor multigene family

FGFR activation in skeletal disorders: too much of a good thing

The genetics of transitional cell carcinoma: progress and potential clinical application.

Molecular alterations in bladder cancer.

The natural history of bladder cancer. Implications for therapy.

A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene

Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

P304

1955-1959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)64665-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

158

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11395371

http://www.w3.org/2001/XMLSchema#string

P932

1891972

http://www.w3.org/2001/XMLSchema#string